Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hanmi Pharm. Co., Ltd. (128940.KS)
KRW356,500.00
-25,000.00 (-6.55%)
KR KSC Healthcare Drug Manufacturers - Specialty & Generic
Address
14, Wiryeseong-daero 5545
Seoul, KR
Seoul, KR
CEO
Jae-Hyun Park
Website
hanmipharm.com
IPO
2010-07-30
ISIN KR7128940004
Description
A globally active pharmaceutical company, Hanmi Pharm. Co., Ltd. was established in Seoul, South Korea, in 1973. The firm concentrates its efforts on researching and developing medical therapies for a range of health issues, including diabetes, obesity, cancer, autoimmune disorders, and various rare diseases.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
KRW356,500.00
-25,000.00 (-6.55%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
135.5K
Beta
0.46
Float Shares
6.26M
Free Float %
49.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.32% | +4.48% | -9.10% | -25.98% | -5.21% | +2.60% | +68.65% | +53.51% | +40.62% | -4.51% | +643.09% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
356,500.00
DCF (Unlevered)
718,671.75
+101.6%
DCF (Levered)
442,055.96
+24.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 8 | 0 |
| Buy | 7 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
5.67
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+3.5% Q1'26: +0.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+39.7% ★ Q1'26: +5.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+5.7% Q1'26: +0.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+14.5% ★ Q1'26: +13.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+12.1% ★ Q1'26: +11.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+1.0% Q1'26: +7.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.35× Q1'26: 2.02× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 13 Rev. Ana. 11 EPS Ana. |
Dec 2027 15 Rev. Ana. 15 EPS Ana. |
Dec 2028 6 Rev. Ana. 7 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.32T
est: 1.32T (+0.0%)
|
882.72B
est: 922.11B (-4.3%)
|
916.59B
est: 918.60B (-0.2%)
|
1.02T
est: 1.01T (+1.1%)
|
1.11T
est: 1.12T (-0.2%)
|
1.08T
est: 1.07T (+0.4%)
|
1.20T
est: 1.18T (+1.8%)
|
1.33T
est: 1.34T (-0.8%)
|
1.49T
est: 1.47T (+1.5%)
|
1.50T
est: 1.53T (-2.6%)
|
1.55T
est: 1.53T (+1.0%)
|
1.65T
1.60T – 1.71T
+7.8% YoY
|
1.82T
1.68T – 1.96T
+10.4% YoY
|
1.91T
1.80T – 2.02T
+4.9% YoY
|
| EBITDA |
271.98B
est: 230.42B (+18.0%)
|
56.85B
est: 161.28B (-64.8%)
|
106.52B
est: 160.66B (-33.7%)
|
116.89B
est: 175.78B (-33.5%)
|
163.68B
est: 195.10B (-16.1%)
|
108.34B
est: 187.50B (-42.2%)
|
209.36B
est: 206.78B (+1.3%)
|
249.04B
est: 234.71B (+6.1%)
|
323.34B
est: 257.03B (+25.8%)
|
292.96B
est: 377.18B (-22.3%)
|
322.68B
est: 376.60B (-14.3%)
|
405.83B
393.27B – 419.21B
+7.8% YoY
|
448.21B
411.84B – 481.59B
+10.4% YoY
|
470.19B
443.36B – 495.83B
+4.9% YoY
|
| EBIT |
221.85B
est: 142.18B (+56.0%)
|
18.07B
est: 99.51B (-81.8%)
|
69.55B
est: 99.14B (-29.8%)
|
69.77B
est: 108.46B (-35.7%)
|
108.27B
est: 120.39B (-10.1%)
|
47.00B
est: 115.69B (-59.4%)
|
120.28B
est: 127.59B (-5.7%)
|
152.20B
est: 144.83B (+5.1%)
|
223.78B
est: 158.59B (+41.1%)
|
195.63B
est: 298.95B (-34.6%)
|
223.88B
est: 298.49B (-25.0%)
|
321.67B
311.71B – 332.27B
+7.8% YoY
|
355.25B
326.43B – 381.71B
+10.4% YoY
|
372.67B
351.41B – 393.00B
+4.9% YoY
|
| Net Income |
154.44B
est: 168.37B (-8.3%)
|
23.33B
est: 58.19B (-59.9%)
|
60.43B
est: 64.99B (-7.0%)
|
34.16B
est: 33.87B (+0.8%)
|
52.11B
est: 50.90B (+2.4%)
|
11.96B
est: 13.05B (-8.4%)
|
67.03B
est: 67.40B (-0.6%)
|
82.79B
est: 89.72B (-7.7%)
|
146.23B
est: 142.65B (+2.5%)
|
121.32B
est: 156.12B (-22.3%)
|
170.48B
est: 168.35B (+1.3%)
|
187.98B
168.39B – 225.16B
+11.7% YoY
|
229.43B
158.25B – 296.76B
+22.0% YoY
|
236.98B
219.40B – 253.78B
+3.3% YoY
|
| SGA |
315.28B
est: 222.56B (+41.7%)
|
172.03B
est: 155.78B (+10.4%)
|
169.81B
est: 155.19B (+9.4%)
|
169.76B
est: 169.79B (0.0%)
|
190.96B
est: 188.45B (+1.3%)
|
181.94B
est: 181.11B (+0.5%)
|
213.38B
est: 199.73B (+6.8%)
|
233.63B
est: 226.71B (+3.1%)
|
248.24B
est: 248.26B (0.0%)
|
233.69B
est: 252.21B (-7.3%)
|
225.89B
est: 251.82B (-10.3%)
|
271.37B
262.97B – 280.32B
+7.8% YoY
|
299.71B
275.39B – 322.03B
+10.4% YoY
|
314.40B
296.47B – 331.55B
+4.9% YoY
|
| EPS |
12,307.00
est: 13,277.46 (-7.3%)
|
1,860.59
est: 4,589.07 (-59.5%)
|
4,965.22
est: 5,124.79 (-3.1%)
|
2,735.74
est: 2,670.97 (+2.4%)
|
4,008.72
est: 4,014.00 (-0.1%)
|
939.25
est: 1,029.32 (-8.8%)
|
5,269.74
est: 5,315.01 (-0.9%)
|
6,517.20
est: 7,074.88 (-7.9%)
|
11,522.00
est: 11,249.48 (+2.4%)
|
9,567.28
est: 12,186.33 (-21.5%)
|
13,371.00
est: 13,141.37 (+1.7%)
|
14,673.62
13,143.99 – 17,575.89
+11.7% YoY
|
17,908.92
12,352.89 – 23,164.61
+22.0% YoY
|
18,498.04
17,126.18 – 19,809.69
+3.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-15 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
34.17B
OE per share TTM
3,558.28
Owner's Yield
0.52%
Maintenance CapEx ratio
95.52%
Maint CapEx / Avg PPE
68.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
98.62M
Shares Outstanding
12.68M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jae-Hyun Park | Chief Executive Officer & Director | 587M | male |
| Lim Chong-Yoon | President of Business Development & Executive Director | 521M | male |
| Byung-hwa Shim | Chief Finance Officer | — | — |
| Jong-Soo Woo | Executive Director | — | male |
| Yang-Hwan Choi | Group Head of IR | — | — |
| Jong-Ho Lim | Executive Director & Management Planning /CIO | — | male |
| Chang-Ju Choi | Vice President of Information Management Team | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 128940.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
